BIOMARKERS: CAN THEY REALLY GUIDE OUR DAILY PRACTICE?

ABSTRACT Optimal management of septic patients requires accurate assessment of both current severity status and prognosis. Since the 1990s, substantial advances have been made in the use of circulating biomarkers for such assessments. This summary of the session on “Biomarkers: can they really use guide our daily practice?” presented at the 2021 WEB-CONFERENCE OF THE EUROPEAN SHOCK SOCIETY, 6 November 2021. These biomarkers include ultrasensitive detection of bacteremia, circulating soluble urokina-type plasminogen activator receptor (suPAR), C-reactive protein (CRP) and ferritin and procalcitonin. In addition, the potential application of novel multiwavelength optical biosensor technology allows noninvasive monitoring of multiple metabolites that can be used to assess severity and prognosis in septic patients. The application these biomarkers and improved technologies provide the potential for improved personalized management of septic patients.

[1]  M. Netea,et al.  IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19 , 2022, Journal of Innate Immunity.

[2]  M. Netea,et al.  Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial , 2021, Nature Medicine.

[3]  J. Lieberman,et al.  Inflammasome activation at the crux of severe COVID-19 , 2021, Nature Reviews Immunology.

[4]  H. Reikvam,et al.  Hyperferritinemia—A Clinical Overview , 2021, Journal of clinical medicine.

[5]  E. Giamarellos‐Bourboulis,et al.  Biomarkers in sepsis: can they help improve patient outcome? , 2021, Current Opinion in Infectious Diseases.

[6]  M. Netea,et al.  An open label trial of anakinra to prevent respiratory failure in COVID-19 , 2020, medRxiv.

[7]  E. Giamarellos‐Bourboulis,et al.  Procalcitonin to Reduce Long-Term Infection-associated Adverse Events in Sepsis. A Randomized Trial , 2020, American journal of respiratory and critical care medicine.

[8]  K. Stamatelopoulos,et al.  A novel optical biosensor for the early diagnosis of sepsis and severe Covid-19: the PROUD study , 2020, BMC Infectious Diseases.

[9]  N. Rovina,et al.  Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia , 2020, Critical Care.

[10]  D. Leaf,et al.  Soluble Urokinase Receptor and Acute Kidney Injury. , 2020, The New England journal of medicine.

[11]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[12]  J. Powers,et al.  Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis. , 2019, Chest.

[13]  Yi Wu,et al.  The Multiple Faces of C-Reactive Protein—Physiological and Pathophysiological Implications in Cardiovascular Disease , 2019, Molecules.

[14]  Yunxia Lu,et al.  The diagnostic accuracy of procalcitonin and C‐reactive protein for sepsis: A systematic review and meta‐analysis , 2015, Journal of cellular biochemistry.

[15]  M. Nijsten,et al.  Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials , 2018, Critical Care.

[16]  R. Fowler,et al.  Systematic Review and Meta-Analysis of Procalcitonin-Guidance Versus Usual Care for Antimicrobial Management in Critically Ill Patients: Focus on Subgroups Based on Antibiotic Initiation, Cessation, or Mixed Strategies* , 2018, Critical care medicine.

[17]  G. Schulert,et al.  Convergent pathways of the hyperferritinemic syndromes , 2018, International immunology.

[18]  G. Kaplanski.  Interleukin‐18: Biological properties and role in disease pathogenesis , 2017, Immunological reviews.

[19]  J. Carcillo,et al.  Hyperferritinemia and inflammation , 2017, International immunology.

[20]  Michael R Broyles.  Impact of Procalcitonin-Guided Antibiotic Management on Antibiotic Exposure and Outcomes: Real-world Evidence , 2017, Open forum infectious diseases.

[21]  M. Netea,et al.  IL-1β/IL-6/CRP and IL-18/ferritin: Distinct Inflammatory Programs in Infections , 2016, PLoS pathogens.

[22]  Tom Dormans,et al.  Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. , 2016, The Lancet. Infectious diseases.

[23]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[24]  Hairong Wang,et al.  Prognostic significance of APACHE II score and plasma suPAR in Chinese patients with sepsis: a prospective observational study , 2015, BMC Anesthesiology.

[25]  R. Thiele,et al.  Advances in photoplethysmography: beyond arterial oxygen saturation , 2015, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.

[26]  P. Sève,et al.  Adult-onset Still's disease. , 2014, Autoimmunity reviews.

[27]  M. Netea,et al.  Deficient Candida-specific T-helper 17 response during sepsis. , 2012, The Journal of infectious diseases.

[28]  I. Dimopoulou,et al.  Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor , 2012, Critical Care.

[29]  F. Tacke,et al.  Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review , 2012, Intensive Care Medicine.

[30]  C. Dinarello,et al.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.

[31]  P. Hellström,et al.  Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy , 2011, Scandinavian journal of gastroenterology.

[32]  F. Tubach,et al.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.

[33]  M. Menshikov,et al.  Release of the Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) by Activated Neutrophils in Rheumatoid Arthritis , 2010, Inflammation.

[34]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[35]  H. Ullum,et al.  Soluble Urokinase Receptor Levels in Plasma During 5 Years of Highly Active Antiretroviral Therapy in HIV-1–Infected Patients , 2004, Journal of acquired immune deficiency syndromes.

[36]  J. Benach,et al.  Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases , 2002, Journal of Neuroimmunology.

[37]  J. Parner,et al.  The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[38]  F. Brunkhorst,et al.  Kinetics of procalcitonin in iatrogenic sepsis , 1998, Intensive Care Medicine.

[39]  N. Brünner,et al.  The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. , 1998, Cancer research.

[40]  L. Weng,et al.  Procalcitonin-guided antibiotic therapy in intensive care unit patients: a systematic review and meta-analysis , 2017 .

[41]  M. Govoni,et al.  Adult-onset Still’s disease , 2009, Rheumatology International.